Treating Invasive Fungal Infections: How Are We Doing?
  • CME
  • CE

This interactive video module reviews the epidemiology and outcomes trends for IFI in high-risk patients, guideline recommendations for primary antifungal therapy, and the advantages and disadvantages of current treatment options.
Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA
George R. Thompson III, MD, FIDSA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 24, 2019 Expiration: April 23, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare the benefits and risks of antifungal agents recommended for high-risk patients with probable or proven IFI

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Thomas F. Patterson, MD, FACP, FIDSA

Professor and Chief
Division of Infectious Diseases
Department of Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, Texas

Thomas F. Patterson, MD, FACP, FIDSA, has disclosed that he has received consulting fees from Basilea, Gilead Sciences, Merck, and Scynexis and funds for research support from Cidara.

Faculty

James Lewis, PharmD, FIDSA

Infectious Diseases Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Associate Professor

Pharmacy & Infectious Diseases
Orgeon Health & Science University
Portland, Oregan

James Lewis, PharmD, FIDSA, has disclosed that he has received consulting fees from Merck.
George R. Thompson III, MD, FIDSA

Associate Professor of Medicine
Division of Infectious Diseases
Department of Internal Medicine
Department of Medical Microbiology and Immunology
University of California – Davis Health
Sacramento, California

George R. Thompson III, MD, FIDSA, has disclosed that he has received consulting fees and funds for research support from Amplyx, Astellas, Cidara, F2G, and Scynexis.

Staff

Megan K. Murphy, PhD

Associate Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, MS, RVT, has disclosed that she has received fees for non-CME/CE activities from Genomic Health, Lilly, and Merck.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for infectious diseases specialists, pulmonologists, intensive care clinicians, hematology/oncology specialists, pharmacists, nurses, and other healthcare providers who care for patients with or at risk for invasive fungal infections.

Goal

The goal of this activity is to improve participants’ competence in applying current and emerging treatment strategies in the management of severely immunocompromised patients at risk for invasive fungal infections.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008176-0000-20-001-H01-P)

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 24, 2019, through April 23, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides on emerging therapies with novel MoAs for invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
Released: April 24, 2019

Downloadable slides with guidance on treatment of invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis in high-risk patients

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA
Released: April 24, 2019

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
George R. Thompson III, MD, FIDSA
Released: April 24, 2019

CME-certified video from CCO on emerging therapies with novel MoAs for invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expiration: April 23, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Astellas

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?